Glutathione S-transferase P1 genotype and prognosis in Hodgkin's lymphoma

Stefan Hohaus, Annalisa Di Ruscio, Annalaura Di Febo, Giuseppina Massini, Francesco D'Alo', Francesco Guidi, Giovanna Mansueto, Maria Teresa Voso, Giuseppe Leone

Research output: Contribution to journalArticlepeer-review


Purpose: Glutathione S-transferase P1 (GSTP1) is a member of the GST enzyme superfamily that is important for the detoxification of several cytotoxic drugs and their byproducts. A single nucleotide polymorphism results in the substitution of isoleucine (Ile) to valine (Val) at codon 105, causing a metabolically less active variant of the enzyme. We assessed the impact of the GSTP1 codon 105 genotype on treatment outcome in patients with Hodgkin's lymphoma. Experimental Design: The Ile105Val polymorphism in the GSTP1 gene was analyzed using a PCR-RFLP technique. Ninety-seven patients with Hodgkin's lymphoma were included and associations with patient characteristics and treatment outcome were analyzed. Results: The GSTP1 Ile105Val polymorphism was associated in a dose-dependent fashion with an improved failure-free survival in patients with Hodgkin's lymphoma (P = 0.02). The probability of 5-year survival for patients homozygous for the 105Val/105 Val GSTP1 genotype was 100%, for heterozygous patients 74% (95% confidence interval, 56-85), and for patients homozygous for the 105Ile/105Ile genotype 43% (95% confidence interval, 23-61). The Cox multivariate analysis showed that GSTP1 codon 105 genotype was an independent prognostic factor. Conclusions: The GSTP1 genotype predicts clinical outcome in patients with Hodgkin's lymphoma.

Original languageEnglish
Pages (from-to)2175-2179
Number of pages5
JournalClinical Cancer Research
Issue number6
Publication statusPublished - Mar 15 2005

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Glutathione S-transferase P1 genotype and prognosis in Hodgkin's lymphoma'. Together they form a unique fingerprint.

Cite this